Hansoh Pharmaceutical Group Company Limited (HNSPF)

Overview

Hansoh Pharmaceutical Group Company Limited, headquartered in Shanghai, People's Republic of China, was established in 1995 and operates as an investment holding entity focused on pharmaceutical innovations. The firm is primarily engaged in the research, development, manufacture, and distribution of an extensive array of pharmaceutical products within China. Catering to various therapeutic areas, they have established a robust product portfolio addressing anti-tumor, anti-infectives, central nervous system diseases, metabolic diseases, among other areas. Hansoh Pharmaceutical has established strategic collaborations with entities like NiKang Therapeutics, TiumBio, Global Health Drug Discovery Institute, KiOmed Pharma SA, and Biotheus Inc. to enhance its research, development, and commercialization capabilities across various segments of the pharmaceutical industry.

Products and Services

Hansoh Pharmaceutical offers a wide range of pharmaceutical products catering to different therapeutic needs. Below are some of their principal offerings:

• Mailingda, Ameile, Hansoh Xinfu, Fulaimei, Hengmu, Xinwei, Tanneng, Ameining, Oulanning, Ailanning, Zetan, Ruibote, Fulaidi, Puruian, Fulairui, Pulaile, Zefei, Xinmei, Xintai, and Gainuo: These drugs encompass Hansoh Pharmaceutical's main product lineup. Although specifics are not provided for each, they are indicated for a variety of therapeutic areas, reflecting the company's broad focus on addressing a range of health issues from anti-tumor to metabolic diseases.
• XINYUE and Hengsen: Also part of their core product suite, these offerings further underscore the company's dedication to providing comprehensive healthcare solutions.
• Collaboration Products and Developments: Through strategic partnerships, Hansoh is working on innovative treatments, including NKT2152 with NiKang Therapeutics for undisclosed indications, TU2670 with TiumBio for the treatment of endometriosis and uterine fibroids, the GDI-4405 series with Global Health Drug Discovery Institute targeting anti-novel coronavirus solutions, KiOmedinevsOne with KiOmed Pharma SA for osteoarthritis, and PM1080 with Biotheus Inc. for unspecified therapeutic uses. These collaborations extend Hansoh's capabilities in new product development and diversification into new therapeutic areas.